Pharmacogenomic Testing in Current Clinical Practice
Implementation in the Clinical Laboratory
Herausgegeben:Wu, Alan H. B.; Yeo, Kiang-Teck J.
Pharmacogenomic Testing in Current Clinical Practice
Implementation in the Clinical Laboratory
Herausgegeben:Wu, Alan H. B.; Yeo, Kiang-Teck J.
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use.…mehr
- Pharmacogenomic Testing in Current Clinical Practice110,99 €
- Hematopathology147,99 €
- Hematopathology147,99 €
- Hepatitis B Virus in Human Diseases63,99 €
- Maryam YavariHot and Cold Theory: The Path Towards Personalized Medicine74,99 €
- Maryam YavariHot and Cold Theory: The Path Towards Personalized Medicine95,99 €
- Personalized Medicine in Anesthesia, Pain and Perioperative Medicine103,99 €
-
-
-
- Produktdetails
- Molecular and Translational Medicine
- Verlag: Humana / Humana Press / Springer, Berlin
- Artikelnr. des Verlages: 978-1-61779-726-2
- Repr. d. Ausg. v. 2011
- Seitenzahl: 288
- Erscheinungstermin: 19. April 2013
- Englisch
- Abmessung: 235mm x 155mm x 16mm
- Gewicht: 444g
- ISBN-13: 9781617797262
- ISBN-10: 161779726X
- Artikelnr.: 37537737
- Molecular and Translational Medicine
- Verlag: Humana / Humana Press / Springer, Berlin
- Artikelnr. des Verlages: 978-1-61779-726-2
- Repr. d. Ausg. v. 2011
- Seitenzahl: 288
- Erscheinungstermin: 19. April 2013
- Englisch
- Abmessung: 235mm x 155mm x 16mm
- Gewicht: 444g
- ISBN-13: 9781617797262
- ISBN-10: 161779726X
- Artikelnr.: 37537737
Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice.
Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu
Chapter 2. Molecular Diagnostic Methods in Pharmacogenomics
Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo
Chapter 3. Economics of pharmacogenomic testing in clinical practice
Alan H.B. Wu
Chapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter 12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice.
Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu
Chapter 2. Molecular Diagnostic Methods in Pharmacogenomics
Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo
Chapter 3. Economics of pharmacogenomic testing in clinical practice
Alan H.B. Wu
Chapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter 12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice.
Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu
Chapter 2. Molecular Diagnostic Methods in Pharmacogenomics
Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo
Chapter 3. Economics of pharmacogenomic testing in clinical practice
Alan H.B. Wu
Chapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter 12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice.
Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu
Chapter 2. Molecular Diagnostic Methods in Pharmacogenomics
Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo
Chapter 3. Economics of pharmacogenomic testing in clinical practice
Alan H.B. Wu
Chapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter 12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Part 4. Drugs that cause delayed hypersensitivity
Chapter12. Abacavir
Elizabeth J. Phillips, Simon A. Mallal
Chapter 13. Allopurinol
Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Chapter 14. Carbamazepine and its structurally-related antiepiletics
Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen
Part 5........ Miscellaneous drugs
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
"The book is written for clinical laboratory directors 'contemplating or assigned the task of establishing a pharmacogenomics laboratory,' pharmacologists, and interested clinicians who may have to interpret results. This book also would be of interest to ... allied health practitioners, regulators, reimbursers, and test device manufacturers. ... The writing is concise, clear, and accessible for what might be considered a complex topic. ... Get this book if you want a quick, concise, and fascinating read about the current world and use of pharmacogenomic testing." (Valerie L. Ng, Doody's Review Service, May, 2011)